On the chart you can see the default numbers in dynamics for Eli Lilly and Company (LLY). Companys revenue shows the average of 14799.641 M which is 0.068 % gowth. The average gross profit for the whole period is 11496.433 M which is 0.074 %. The average gross profit ratio is 0.771 %. The net income growth for the company last year performance is -0.161 % which equals 0.532 % % on average for the whole company history.,
Diving into the fiscal trajectory of Eli Lilly and Company, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.293. In the realm of current assets, LLY clocks in at 25727 in the reporting currency. A significant portion of these assets, precisely 2927.7, is held in cash and short-term investments. This segment shows a change of 0.324% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 3052.2, if any, in the reporting currency. This indicates a difference of 5.183% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 18320.8 in the reporting currency. This figure signifies a year_over_year change of 0.553%. Shareholder value, as depicted by the total shareholder equity, is valued at 10771.9 in the reporting currency. The year over year change in this aspect is 0.011%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 11336.2, with an inventory valuation of 5772.8, and goodwill valued at 4939.7, if any. The total intangible assets, if present, are valued at 6906.6. Account payables and short-term debt are 2598.8 and 6904.5, respectively. The total debt is 25225.3, with a net debt of 22406.7. Other current liabilities amount to 3281.3, adding to the total liabilities of 53142.6. Lastly, the referred stock is valued at 0, if it exists.
The financial landscape of Eli Lilly and Company has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -1.685. The company recently extended its share capital by issuing -8649.9, marking a difference of -0.084 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -7152700000.000 in the reporting currency. This is a shift of 1.193 from the previous year. In the same period, the company recorded 1527.3, 1412.4, and -8649.9, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated -4069.3 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 25614.7, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.
Eli Lilly and Company's revenue saw a change of 0.196% compared with the previous period. The gross profit of LLY is reported to be 27548.1. The company's operating expenses are 17222.7, showing a change of 26.348% from the last year. The expenses for depreciation and amortization are 1527.3, which is a -0.338% change from the last accounting period. Operating expenses are reported to be 17222.7, which shows a 26.348% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a 0.449% year-over-year growth. The operating income is 10325.4, which shows a 0.449% change when compared to the previous year. The change in the net income is -0.161%. The net income for the last year was 5240.4.
